Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
India’s efforts are aimed at boosting health at the last mile
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
Both the companies intend to facilitate faster clinical trial enrollment and provide patients with access to novel medications
Subscribe To Our Newsletter & Stay Updated